Pharmacogenetics of hypoglycemic agents | Zendy

Ирина Владимировна Кононенко | Zendy; Alexander Yur'evich Mayorov | Zendy; Екатерина Олеговна Кокшарова | Zendy; М. В. Шестакова | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacogenetics of hypoglycemic agents

Author(s) -

Ирина Владимировна Кононенко,

Alexander Yur'evich Mayorov,

Екатерина Олеговна Кокшарова,

М. В. Шестакова

Publication year - 2015

Publication title -

diabetes mellitus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.155

H-Index - 12

eISSN - 2072-0378

pISSN - 2072-0351

DOI - 10.14341/dm7681

Subject(s) - medicine , sulfonylurea , metformin , pharmacogenetics , glycemic , diabetes mellitus , pharmacology , glucagon like peptide 1 , troglitazone , bioinformatics , type 2 diabetes , endocrinology , receptor , gene , genotype , genetics , biology , peroxisome

Despite the increase in the number of hypoglycemic agents, 35%–40% of patients with diabetes are unable to achieve adequate glycemic control. One of the reasons is the genetic heterogeneity of diabetes mellitus, requiring different treatment approaches; however, the individual metabolic features and sensitivity to drugs also affect the therapeutic effectiveness. The review presents the main results of pharmacogenetic research of several antidiabetic drugs: metformin, sulfonylurea, agonists of glucagon-like peptide-1 and thiazolidinediones.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research